PAM50基因突变与即刻乳房重建术治疗乳腺癌疗效的关系及对术后生存的预测-现代医学

PAM50基因突变与即刻乳房重建术治疗乳腺癌疗效的关系及对术后生存的预测

单位：1. 邢台市第三医院腺体外科, 河北邢台 054000;
2. 邢台市沙河市人民医院腺体外科, 河北邢台 054100

分类号：R737.9

出版年·卷·期（页码）：2021·50·第七期（724-728）

摘要：

目的：研究PAM50基因突变与即刻乳房重建术治疗的乳腺癌患者疗效的关系及对患者术后生存期的预测价值。方法：选取2016年8月至2017年8月邢台市第三医院收治的124例乳腺癌患者，均行即刻乳房重建术治疗。收集患者年龄、分型、临床获益、无进展生存时间、PAM50基因突变情况等病例资料，根据PAM50基因突变情况分为突变组和无突变组，比较两组患者病例资料差异。采用多因素Logistic回归分析影响乳腺癌疗效的因素，采用受试者工作特征（ROC）曲线分析PAM50基因突变预测术后生存的价值。结果：124例乳腺癌患者中PAM50基因突变28例（22.58%），其中突变组患者的临床获益率、无进展生存时间明显低于或者短于无突变组（P<0.05）。Logistic回归分析显示，PAM50基因突变（OR=2.146，95%CI 1.198~3.831）、TNM分期（OR=2.846，95%CI 1.230~6.586）均是影响治疗效果的危险因素（P<0.05）。入组患者随访3年，死亡45例（36.29%），其中突变组死亡15例（53.57%），未突变组死亡30例（31.25%），两组死亡率差异有统计学意义（χ²=4.671，P=0.031）。ROC曲线分析显示，PAM50基因突变预测术后3年生存的曲线下面积为0.813（95%CI 0.752~0.896），特异度、敏感度分别为76.6%、77.8%。结论：乳腺癌患者PAM50基因突变是影响即刻乳房重建术治疗效果的危险因素，并对术后生存情况具有较高的预测价值。

Objective: To study the relationship between PAM50 gene mutation and the curative effect of breast cancer patients undergoing immediate breast reconstruction and its predictive value for postoperative survival. Methods: 124 patients with breast cancer in Xingtai Third Hospital from August 2016 to August 2017 were selected and treated with immediate breast reconstruction. The patients age, pathological type, clinical benefit, progression free survival time, PAM50 gene mutation were collected. According to with or withoutPAM50 gene mutation, they were divided into mutation group and non-mutation group, and the differences of medical records between the two groups were compared. Multivariate Logistic regression analysis was used to analyze the risk factors affecting the treatment efficacy of breast cancer. Receiver operating characteristic(ROC) curve was used to analyze the value of PAM50 gene mutation in predicting postoperative survival. Results: Among the 124 breast cancer patients, 28 (22.58%) had PAM50 gene mutation, and the clinical benefit rate and progression free survival time of the mutation group were significantly lower than or shorter than those of the non-mutation group(P<0.05). Logistic regression analysis showed that PAM50 gene mutation(OR=2.146，95%CI 1.198-3.831)and TNM stage(OR=2.846，95%CI 1.230-6.586)wererisk factors of treatment effect(P< 0.05). After following up 3 years, 45 cases(36.29%) died, including 15 cases (53.57%) in mutation group and 30 cases (31.25%) in non-mutation group. The mortality difference between the two groups was statistically significant (χ²=4.671, P=0.031). ROC curve analysis showed that the AUC of PAM50 gene mutation predicting 3-year survival was 0.813 (95%CI 0.752-0.896), and the specificity and sensitivity were 76.6% and 77.8%, respectively.Conclusion: PAM50 gene mutation, which has high predictive value for postoperative survival, in breast cancer patients is a risk factor affecting the treatment efficacy of immediate breast reconstruction.

参考文献：

[1] ANDERSSON Y, BERGKVIST L, FRISELL J, et al.Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes[J].Breast Cancer Res Tr, 2018, 171(2):359-369.
[2] 郑舒月, 苏永辉, 郭瑢, 等.2017年中国110家医院乳腺癌保乳手术的现况调查[J].中华普通外科杂志, 2020, 35(4):314-318.
[3] 郭瑢, 曹阿勇, 邵志敏, 等.中国乳腺癌术后植入物乳房重建现况调查[J].中华外科杂志, 2019, 57(8):616-621.
[4] ZENG Y, WANG C L, XIAN J, et al.Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer[J].Onco Targets Ther, 2019, 12(1):7193-7201.
[5] PU M, MESSER K, DAVIES S R, et al.Research-based PAM50 signature and long-term breast cancer survival[J].Breast Cancer Res Treat, 2020, 179(1):197-206.
[6] PRAT A, PARKER J S.Standardized versus research-based PAM50 intrinsic subtyping of breast cancer[J].Clin Transl Oncol, 2020, 22(6):953-955.
[7] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志, 2017, 27(9):695-759.
[8] 中华医学会外科学分会乳腺外科学组.早期乳腺癌保留乳房手术中国专家共识(2019版)[J].中华外科杂志, 2019, 57(2):E001.
[9] 马建勋, 夏有辰, 李比, 等.组织扩张结合假体乳房重建的技术改进[J].北京大学学报(医学版), 2020, 52(1):175-182.
[10] 徐元兵, 黄晓燕, 陈嘉健, 等.保留乳头乳晕乳房切除术联合即刻乳房重建手术中乳头乳晕安全性保留预测模型的建立[J].中国实用外科杂志, 2020, 40(8):957-963.
[11] 刘钟芬, 陈创, 姚晓莉, 等.乳腺癌不同分子分型的临床病理特点及预后分析[J].中华医学杂志, 2016, 96(22):1733-1737.
[12] 张虎, 杜欣娜, 凌存宝, 等.基于多组学高通量数据分析乳腺癌中8号染色体开放阅读框33的表达和预后[J].中国老年学杂志, 2019, 39(11):2628-2630.
[13] FILIPITS M, NIELSEN T O, RUDAS M, et al.The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer[J].Clin Cancer Res, 2014, 20(5):1298-1305.
[14] CHRISTENSEN L G, LAUTRUP M D, LYNG M B, et al.Subtyping of male breast cancer by PAM50 and immunohistochemistry:a pilot study of a consecutive Danish cohort[J].APMIS, 2020, 128(9):523-530.
[15] OCHOA S, DE ANDA-JÁUREGUI G, HERNÁNDEZ-LEMUS E.Multi-omic regulation of the PAM50 gene signature in breast cancer molecular subtypes[J].Front Oncol, 2020, 10(1):845.
[16] 张虎, 杜欣娜, 庄莹, 等.乳腺癌中跨膜蛋白81基因高表达不利于患者预后[J].中国临床解剖学杂志, 2018, 36(5):586-589.
[17] DOWSETT M, SESTAK I, LOPEZ-KNOWLES E, et al.Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy[J].J Clin Oncol, 2013, 31(22):2783-2790.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录